Y Intercept Hong Kong Ltd Has $10.76 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Y Intercept Hong Kong Ltd boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 199.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 125,081 shares of the company’s stock after acquiring an additional 83,364 shares during the period. Novo Nordisk A/S comprises about 0.7% of Y Intercept Hong Kong Ltd’s portfolio, making the stock its 7th largest position. Y Intercept Hong Kong Ltd’s holdings in Novo Nordisk A/S were worth $10,759,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $28,000. Center for Financial Planning Inc. raised its holdings in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Novo Nordisk A/S during the third quarter valued at about $42,000. Dunhill Financial LLC boosted its holdings in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after buying an additional 311 shares in the last quarter. Finally, Albion Financial Group UT grew its position in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of a number of analyst reports. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Up 5.2 %

NVO stock opened at $88.07 on Monday. The firm has a market cap of $395.19 billion, a P/E ratio of 26.77, a PEG ratio of 0.90 and a beta of 0.45. The company’s 50-day simple moving average is $86.01 and its 200-day simple moving average is $107.99. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52-week low of $77.82 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.